Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

Lancet

Volumn 352, Issue 9134, 1998, Pages 1087-1092

  Gratwohl, A ^a   Hermans, J ^k   Goldman, J M ^b   Arcese, W ^c   Carreras, E ^d   Devergie, A ^e   Frassoni, F ^f   Gahrton, G ^g   Kolb, H J ^h   Niederwieser, D ⁱ   Ruutu, T ^k   Vernant, J P ^j   De Witte, T ^k   Apperley, J ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c Sapienza   (Italy)

^d HOSPITAL CLÍNIC   (Spain)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF GENOA   (Italy)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ University Hospital for Internal Medicine   (Austria)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT COUNSELING; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0032480589     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03030-X     Document Type: Article

References (25)

1. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996; 100: 55-70.
2. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82: 478-95.
3. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114: 532-38.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-25.
5. Hehlmann R, Heimpel H, Hossfeld DK, et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone Marrow Transplant 1996; 17 (suppl 3): S21-24.
6. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha 2-b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223-29.
7. van Rhee F, Szydlo RM, Hermans J, et al. Long term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the chronic leukemia working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-60.
8. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-56.
9. Fefer A, Cheever MA, Thomas ED, et al. Disappearance of Ph1 positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and bone marrow transplantation from an identical twin. N Engl J Med 1979; 300: 333-37.
10. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-38.
11. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984; i: 665-68.
12. Gratwohl A, Hermans J, Baldomero H. Blood and marrow transplant activity in Europe 1995. Bone Marrow Transplant 1997; 19: 407-19.
13. Goldman JM, Apperley J, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202-07.
14. Gratwohl A, Hermans J, Niederwieser D, et al, for the chronic leukemia working party of the European Group for Blood and Marrow Transplantation EBMT. Bone marrow transplantation for chronic myelogenous leukemia: long term effects. Bone Marrow Transplant 1993; 12: 509.
15. Devergie A, Apperley J, Labopin M, et al. European results of matched unrelated bone marrow transplantation for chronic myeloid leukemia: impact of class II matching. Bone Marrow Transplant 1997; 20: 11-19.
16. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukemia: the effect of leukemia cell burden, HLA-matching and marrow cell dose. Blood 1997; 89: 4226-35.
17. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-68.
18. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposal for standardized reporting of results of bone marrow transplants for leukemia. Bone Marrow Transplant 1989; 4: 445-48.
19. Marubini E, Valsecchi MS, eds. Analysing survival data from clinical trials and observational studies. New York: Wiley, 1995.
20. McGlave PB, De Fabritis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486-88.
21. Lee AJ, Kuntz MK, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997; 127: 1080-88.
22. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for the aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
23. Goldman JM, Szydlo R, Horowitz M, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235-38.
24. Dini G, Rondelli R, Miano M, et al. Unrelated donor bone marrow transplantation for Philadelphia positive chronic myelogenous leukemia in children: experience of eight European countries: the EBMT paediatric disease working party. Bone Marrow Transplant 1996; 18 (suppl 2): 80-85.
25. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon alpha in patients with chronic phase Philadelphia positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981-90.